I’ve been sharing weekly updates of new publications in health economics and genomics on social media for a few weeks, but thought it would be useful if I also presented these updates in weekly blog posts.
There are 2 new publications this week:
- Estimating the Costs of Genomic Sequencing in Cancer Control | pubmed.ncbi.nlm.nih.gov/32493298/
- Next-Generation Sequencing vs Culture-Based Methods for Diagnosing Periprosthetic Joint Infection After Total Knee Arthroplasty: A Cost-Effectiveness Analysis | pubmed.ncbi.nlm.nih.gov/31005439/
As I’m putting these in a blog post for the first time, here are the latest publications from the past four weeks too:
- Making a Genetic Diagnosis in a Level IV Neonatal Intensive Care Unit Population: Who, When, How, and at What Cost? | pubmed.ncbi.nlm.nih.gov/31255390/
- Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment | feat. @DeanRegier, @Basucally, @JoshJCarlson | jmcp.org/doi/10.18553/j
- Return of Genetic and Genomic Research Findings: Experience of a Pediatric Biorepository | pubmed.ncbi.nlm.nih.gov/31775751/
- Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review | feat. @sjwright17, @kp170768, @GeneticBill | pubmed.ncbi.nlm.nih.gov/31087278/
- Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy |feat. @22Kathryn11, @UCSF_TRANSPERS | ncbi.nlm.nih.gov/pubmed/32389216
- Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group | @maartenijzerman, @kp170768 | ncbi.nlm.nih.gov/pubmed/32389217
- Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions | @MDouglas_MS, @22Kathryn11, @UCSF_TRANSPERS | ncbi.nlm.nih.gov/pubmed/32389218
- Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019 | @JuliaTrosman, @UCSF_TRANSPERS, @cebweldon, @22Kathryn11, @AllisonKurian, @MDouglas_MS | ncbi.nlm.nih.gov/pubmed/32389219
- Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing | @ZoeMackay20, @kdchrist, @22Kathryn11 | ncbi.nlm.nih.gov/pubmed/32389220
- Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling | @Marshall_HEcon, @LuizaGrazziotin, @DeanRegier, @jbuchanan_ox, @22Kathryn11, @maartenijzerman | ncbi.nlm.nih.gov/pubmed/32389221
- The personal utility and uptake of genomic sequencing in pediatric and adult conditions: eliciting societal preferences with three discrete choice experiments | @IliasGoranitis, @drstephbest, @TiffBoughtwood, @AusGenomics, @ZornitzaS | ncbi.nlm.nih.gov/pubmed/32371919
- Method for economic evaluation of bacterial whole genome sequencing surveillance compared to standard of care in detecting hospital outbreaks | ncbi.nlm.nih.gov/pubmed/32367125
- Consecutive medical exome analysis at a tertiary center: Diagnostic and health-economic outcomes | ncbi.nlm.nih.gov/pubmed/32369273
Health Economics and Genomics 